Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy (PTCRRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00703144|
Recruitment Status : Completed
First Posted : June 23, 2008
Last Update Posted : January 24, 2013
|Condition or disease||Intervention/treatment||Phase|
|Diffusive and Convective Clearance Body Clearance Piperacillin Tazocilline Concentrations (Cmin)||Drug: piperacillin/tazobactam Procedure: Pharmacokinetic||Phase 4|
The pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration. This is a prospective study.
Continuous replacement therapy has a continuous effect on drug elimination which could compromise effective antibiotic treatment.
Patients will receive a standard course of pip/tazo 4g intravenously 8 hourly administrated immediately when CVVHDF will be started.
Blood samples will be collected at 30mn, 2h, 4h, 6h, 8h, 16h, 24h for the first and the second day.
We will measure plasma piperacillin/tazobactam concentration and compare them to MICs for the whole dosing interval.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Pharmacokinetics of Piperacillin and Tazobactam in Anuric Septic Patients Treated by Continuous Veno Venous Hemodiafiltration|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||August 2012|
|Actual Study Completion Date :||August 2012|
piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
Other Name: TazocillineProcedure: Pharmacokinetic
- Serum levels of both piperacillin and tazobactam (Cmin) during 2 daus [ Time Frame: 2 days ]
- Body clearance [ Time Frame: 2 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00703144
|Service de Néphrologie|
|Toulouse, France, 31059|
|Principal Investigator:||LAVAYSSIERE Laurence, MD||University Hospital, Toulouse|